Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma - Summary - MDSpire

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

Share

Objective:

To evaluate the impact of treatment intensity on outcomes for transplant-ineligible patients with multiple myeloma (MM), emphasizing its significance in the context of evolving therapies.

Key Findings:
  • Quadruplet therapy (Isa-VRd) demonstrated a 60-month progression-free survival (PFS) of 63.2% compared to 45.2% with VRd alone, indicating a significant improvement in treatment efficacy.
  • Sustained minimal residual disease (MRD) negativity for 12 months was higher in the quadruplet therapy group, suggesting better long-term outcomes.
  • The introduction of novel therapies has significantly improved overall survival from approximately 3 years to more than 8 to 10 years, highlighting the transformative impact of these treatments.
Interpretation:

Intensifying treatment from doublet to quadruplet regimens has led to improved outcomes for transplant-ineligible MM patients, underscoring the critical need to balance efficacy with tolerability, especially in an aging population.

Limitations:
  • The trials had differing enrollment criteria and patient populations, which may affect generalizability to the broader MM population.
  • Exclusion criteria varied, potentially limiting the applicability of findings to broader patient demographics, particularly older patients with comorbidities.
Conclusion:

Quadruplet therapy represents a significant advancement in the treatment of transplant-ineligible patients with MM, offering improved efficacy while addressing the specific needs of an aging patient population.

Original Source(s)

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

  • by Mark Davis

  • May 6, 2026

Related Content

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...